Noticias

Keros Therapeutics Authorizes Additional $5 Mln Share Repurchase Program

NASDAQ

(RTTNews) - Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company, on Monday announced that its board of directors has approved an additional $5 million share repurchase program.

Leer el informe completo de Veytics

Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.